AI Governance in Healthcare: Why Certification, Internal Committees, and Continuous Audits Are No Longer Optional

The hospital system that deploys an AI-powered diagnostic tool without a regulatory certification framework is not innovating — it is gambling with patient lives and institutional liability. That distinction is no longer theoretical. In 2025 and 2026, regulators across the United States, the European Union, and Brazil have moved decisively: AI systems in clinical environments are no longer treated as software tools. They are medical devices.

The Regulatory Landscape Has Shifted — Permanently

The FDA's evolving framework for Software as a Medical Device (SaMD) now demands that AI systems used in diagnostics, treatment planning, or patient monitoring undergo pre-market submissions with evidence of clinical validation, algorithmic transparency, and post-market surveillance protocols. In the EU, the AI Act classifies most healthcare AI as "high-risk," triggering mandatory conformity assessments under both the AI Act and the Medical Device Regulation (MDR). In Brazil, ANVISA has been steadily tightening its digital health resolution framework, and hospital executives who have not started mapping their AI portfolio against RDC requirements are already behind.

This isn't abstract policy. Legislative momentum in the US alone has accelerated sharply in 2026, with states adding disclosure mandates and algorithmic accountability provisions that directly affect how clinical AI is deployed and documented.

Certification Is the Floor, Not the Ceiling

Many healthcare executives still treat regulatory certification as a compliance checkbox — something to hand off to legal. That framing is a mistake. Certification is the minimum threshold for market entry; what protects the institution operationally is the governance infrastructure built around it.

Consider what certification actually requires: clinical evidence of performance, defined intended-use populations, bias testing across demographic subgroups, version control documentation, and in many jurisdictions, post-deployment monitoring plans. A hospital system that receives FDA clearance for an AI triage tool but lacks internal processes to track model drift, monitor outcomes by patient cohort, or manage vendor updates is exposed — both clinically and legally.

Illumina's Billion Cell Atlas initiative illustrates precisely how complex the data provenance question becomes in healthcare AI at scale. When models are trained on genomic datasets spanning billions of cells, the accountability chain — who validated what, under which conditions, for which populations — demands institutional rigor that no regulatory stamp alone can provide.

Internal Governance Committees: From Nice-to-Have to Non-Negotiable

The most operationally mature health systems I have advised have established dedicated AI Clinical Governance Committees. These are not IT steering groups repurposed for the AI era. They are cross-functional bodies that include clinical leadership, bioethics representation, data science expertise, legal counsel, and increasingly, patient advocacy input.

Their mandate: evaluate new AI systems before deployment, define clinical use boundaries, oversee performance monitoring, and establish escalation pathways when a system underperforms or behaves unexpectedly. In practical terms, this committee is the institutional memory of why a given AI tool was approved, under what constraints, and what evidence threshold would trigger its suspension.

This structure aligns directly with what Samsung's Trust-by-Design initiative represents at the product level — the principle that governance must be embedded into the system architecture, not layered on after deployment. In healthcare, that principle becomes a clinical imperative.

What These Committees Must Own

• Pre-deployment validation protocols: independent clinical testing beyond vendor-supplied benchmarks
• Vendor contract governance: rights to audit model behavior, access training data documentation, and receive timely disclosure of model updates
• Incident response frameworks: defined procedures when AI outputs contribute to adverse clinical events
• Staff training accountability: ensuring clinicians understand not just how to use the tool, but its known limitations

Continuous Auditing: The Most Underestimated Requirement

If certification opens the door and governance committees manage the threshold, continuous auditing is what keeps the institution safe once the system is live. AI models degrade. Patient populations shift. Data pipelines introduce silent errors. A model that performed at 94% sensitivity during validation may be operating at 87% six months into deployment — and no one in the hospital knows.

The IBM 2026 X-Force Threat Index underscores a related dimension: healthcare AI systems are increasingly targeted by adversarial attacks designed to manipulate model outputs. Continuous auditing must encompass not only clinical performance metrics but also security integrity.

Effective continuous audit programs for healthcare AI include: automated performance dashboards with real-time alerting on statistical thresholds, quarterly clinical outcome reviews tied to AI-assisted decisions, annual third-party algorithmic audits, and documented model lifecycle management — from initial deployment through planned decommissioning.

The Strategic Imperative for Health System Leadership

Regulators are not going to slow down. The TRAIGA framework in Texas signals that even jurisdictions seeking a "middle path" on AI regulation are moving toward mandatory accountability structures. For health systems, the question is no longer whether to build robust AI governance — it is whether to build it proactively on your terms, or reactively under regulatory pressure.

The institutions that will lead in AI-driven care delivery over the next decade are not those that adopt the most models fastest. They are the ones that build the governance infrastructure to use those models safely, accountably, and sustainably. That infrastructure starts now, with certification strategy, internal committee formation, and a continuous auditing culture that treats patient safety as the non-negotiable constant.